# Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.

> **NCT05172050** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 61 (actual)

## Conditions studied

- SARS CoV 2 Infection

## Interventions

- **DRUG:** Raloxifene
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05172050
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-22
- **Primary completion:** 2021-06-12
- **Final completion:** 2021-06-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172050, "Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05172050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*